Company
Cancer is a leading global cause of death and emerges from healthy cells transforming into tumor cells due to genetic factors and external influences.
Despite the variety of over 100 diseases it encompasses, current treatments remain limited and often bring unwanted side effects.
We at YGION are committed to creating precision therapies eliminating tumors without harming patients. Recognizing that every patient and tumor is unique, we strive for customized treatments tailored to each patient’s specific condition.
Our Leadership Team
Founded in 2022 by a group of scientific innovators, YGION has grown into an international, multidisciplinary team dedicated to tackling the challenges of cancer genomics and immunotherapy.
Wolfgang Fischl, PhD
Co-Founder, Chief Executive Officer & Chief Scientific Officer
Georg Casari, PhD
Co-Founder, Chief Executive Officer & Chief Operating Officer
Alexander Seitz, MD
Co-Founder, Advisor
Geert Mudde, PhD
Co-Founder, Chief Technology Officer
Sophie Zettl, PhD
Chief Business Officer
Gottfried Himmler, PhD
Co-Founder, Head of Clinical and Quality Operations
Our Partners
Generously Supported By
